TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01184378

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: dairy lipids and soluble milk proteins
Description: one month formula supplementation feces are collected during a 3 days period after 15 and 30 days of formula intake

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dairy lipids and soluble milk proteins
Description: one month formula supplementation feces are collected during a 3 days period after 15 and 30 days of formula intake
Study: NCT00172094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPS 1776 (800 mg)
Description: NPS 1776 (800 mg) powder

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Placebo in non-carbonated fruit flavored drink (150 ml)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPS 1776 (400 mg)
Description: NPS1776 in powdered form to be mixed with a non-carbonated fruit flavored drink
Study: NCT03558581

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational
Study: NCT03451253

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: amino acid mixture beverage
Description: commercially available amino acid mixture. Contains 5 amino acids, electrolytes and natural flavoring.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: glucose-based sports drink
Description: Commercially available glucose-based sports drink, contains electrolytes, sugar and artificial flavoring.
Study: NCT01598844

Intervention type: DEVICE
Intervention: Transcatheter aortic valve replacement
Description: Transcatheter aortic valve replacement via a transapical access

Intervention type: DEVICE
Intervention: Transcatheter aortic valve replacement
Description: Transcatheter aortic valve replacement via a transapical access
Study: NCT02996227

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAP block
Description: Transversus Abdominis Plane (TAP) blocks will be performed preoperatively. An in-plane ultrasound will be used in TAP block procedure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural analgesia
Description: Epidural catheters will be inserted preoperatively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXPAREL
Description: Once the target area is positioned, plain bupivacaine 0.25%, 20ml will be given to open the space and then single dose (10ml) of liposomal bupivacaine (Exparel) mixed with saline (10 ml) will be injected in each side. Total dose of Exparel will be 20 mL.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Once an epidural catheter is successfully positioned, an infusion will be initiated intraoperatively. Bupivacaine standard solution without additives will be prepared for each patient in epidural group.
Study: NCT02147834

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranolazine
Description: Ranolazine 500mg tablet~1. 500mg tablet two times per day for 7 days then,~2. 500mg tablet (1000mg) two times per day for 15 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: sugar pill manufactured to mimic ranolazine 500mg tablet~1. 500mg tablet two times per day for 7 days then,~2. 500mg tablet (1000mg) two times per day for 15 weeks
Study: NCT00695461

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum 299v in oatmeal drink
Description: Bacteria in a concentration of 10(9) CFU/ml

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Oatmeal drink
Description: Oatmeal drink as in arm 1 but without bacteria added.
Study: NCT00671112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Patients will be assigned to one of the following dose levels of Bortezomib: 0.7mg/m2, 1.0 mg/m2, or 1.3mg/m2 on days 1,4,8,11 of a 21 day cycle.~The appropriate amount of bortezomib will be drawn from the injection vial and administered as an intravenous (IV) push or sub-cutaneously over 3 to 5 seconds followed by a standard saline flush or through a running IV line.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus 5 mg PO every other day, 5 mg by mouth (PO) daily, or 10 mg PO daily
Study: NCT01804946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ergoferon
Description: Safety and Efficiency of Ergoferon in treatment of Influenza

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir
Description: Safety and Efficiency in treatment of Influenza
Study: NCT03096860

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active alcohol consumption
Description: Comparison of alcohol consumption vs. placebo consumption and hookah smoking.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo consumption
Description: Comparison of alcohol consumption vs. placebo consumption and hookah smoking.
Study: NCT03059043

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: viscoelastic-free implantation system
Description: Viscoelastic-free implantation system use balanced salt solution irrigation during the implantation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard viscoelastic-assisted Implantation system
Description: This method utilize the viscoelastic agent to fill and maintain the anterior chamber during the implantation
Study: NCT02859766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abicipar pegol
Description: Abicipar pegol 2 mg administered to the study eye by intravitreal injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abicipar pegol
Description: Abicipar pegol 2 mg administered to the study eye by intravitreal injection.
Study: NCT00063934

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: oblimersen sodium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Description: Given SC
Study: NCT04336254

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: allogeneic human dental pulp stem cells (BSH BTC & Utooth BTC)
Description: Intravenous injection of 3.0x10e7 human dental pulp stem cells solution (30ml) on day 1, day 4 and day 7, based on routine treatment of COVID-19

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous saline injection (Placebo)
Description: Intravenous injection of 3ml of 0.9% saline on day 1, day 4 and day 7, based on routine treatment of COVID-19
Study: NCT00016289

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interleukin-12
Description: Given intraperitoneally
Study: NCT00353275

Intervention type: DRUG
Group type: OTHER
Intervention: Strict Glycemic control
Description: Blood glucose target range is 80-110 mg/dL.
Study: NCT01681979

Intervention type: DRUG
Intervention: Fluticasone propionate (with and without concurrent salmeterol)
Description: Fluticasone propionate is an inhaled corticosteroid used for the treatment of asthma, often in combination with the long-acting β-agonist salmeterol. For the primary endpoint, exposure status will be determined based on the individual receiving a prescription for the drug of interest (fluticasone propionate or another inhaled corticosteroid) in the 2 weeks immediately before the LMP date or during the first trimester of pregnancy.~Sensitivity analysis will be carried out categorising exposure based on mapping the duration of prescriptions based on the number of inhalers, number of puffs within an inhaler and the prescribed daily dose.
Study: NCT04300907

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Provant Infinity Therapy System
Description: Treatment with the Provant Infinity Therapy System, PEMF device
Study: NCT03336645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHP615
Description: SHP615 oromucosal solution will be administered as a single age-specific dose (2.5, 5, 7.5 and 10 mg).
Study: NCT01029080

Intervention type: OTHER
Intervention: no interventions
Description: No interventions
Study: NCT01895088

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcuFocus Corneal Inlay ACI 7000 PDT
Description: Inlay implanted in cornea for improvement of near vision
Study: NCT00758706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1236
Description: oral tablet, 75 mg, twice daily during 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosing to match AZD1236
Study: NCT03232554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buxue Yimu Pills
Description: Buxue Yimu Pills 12g pill by mouth, twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buxue Yimu Pills &Ferrous Sulfate
Description: Buxue Yimu Pills 12g pill by mouth, twice daily and Ferrous Sulfate 0.3g tablet by mouth, three times daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous Sulfate
Description: Ferrous Sulfate 0.3g tablet by mouth, three times daily
Study: NCT02421770

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chamaemelum nobile 2%
Description: Experimental Chamaemelum Nobile 2% gel Active During the 6-week double-blind phase, all patients will be randomly assigned to receive Chamaemelum Nobile 2% gel Active or its vehicle twice daily with occlusion on the affected are

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT01225237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramosetron
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study: NCT01743768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB010
Description: Treatment group (n=19), receiving the active drug substance.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment group (n=19), receiving placebo.
Study: NCT02077660

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Four green tea bags per day for 12 weeks
Description: Four green tea bags per day for 12 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 4 daily placebo tea bags for 12 weeks
Description: 4 daily placebo tea bags for 12 weeks
Study: NCT01643928

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab-Pfizer (PF-05280586) x 3 courses
Description: 1000 mg intravenous infusion \[IV\] on Days 1 and 15 of each 24 week treatment course for up to 3 treatment courses

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab-EU+ Rituximab-Pfizer x 2 Courses
Description: Subjects will receive Rituximab-EU x 1 course followed by Rituximab-Pfizer x 2 courses. 1000 mg IV infusion of Rituximab-EU on Days 1 and 15 of a 24 week treatment course followed by 1000 mg IV infusion of PF-05280586 on Days 1 and 15 of each 24 week course for up to 2 additional treatment courses

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab-US + Rituximab-Pfizer x 2 Courses
Description: Subjects will receive Rituximab-US x 1 course followed by Rituximab-Pfizer x 2 courses. 1000 mg IV infusion of Rituximab-US on Days 1 and 15 of a 24 week treatment course followed by 1000 mg IV infusion of PF-05280586 on Days 1 and 15 of each 24 week course for up to 2 additional treatment courses
Study: NCT01222182

Intervention type: DRUG
Intervention: atorvastatin
Description: All patients desired to change atorvastatin 10, 20mg to an equivalent that is covered by their prescription plan. This is accomplished by either pharmacists by MD/Pharmacist practice agreement or physicians in usual practice
Study: NCT03976349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB094
Description: Administered as specified in the treatment arm.
Study: NCT00353275

Intervention type: DRUG
Group type: OTHER
Intervention: Conventional Glycemic Control
Description: Blood glucose target range is 110-140 mg/dL.
Study: NCT03976349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB094
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB094
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB094
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB094
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB094
Description: Administered as specified in the treatment arm.
Study: NCT01591746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5 mL 0.9% NaCl solution to mimic Botulinum Toxin Type A
Study: NCT00063934

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo surgical resection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Optional correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Optional correlative studies
Study: NCT01408303

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Olive oil, 4g
Description: Olive oil: 4 x 1 g capsule daily for 6 weeks + prescription statin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omega-3-carboxylic acids, 2g
Description: Epanova: 2 x 1 g capsule + olive oil 2 x 1 g capsule daily for 6 weeks + prescription statin
Study: NCT00736996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: 30 - 45mg tablet daily for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching tablet daily for 6 months

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Endurance Exercise Training
Description: Individualized exercise prescription, 45-75 minutes (progressive increments) three times a week
Study: NCT02736084

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Psychology
Description: The Positive Psychology intervention consists of 7 exercises that will be completed by the participant with the guidance of a trainer.
Study: NCT03272438

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accelerometer
Description: Participants use an accelerometer to monitor their steps activity

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Accelerometer
Description: Participants use an accelerometer to monitor their steps activity

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Accelerometer
Description: Participants use an accelerometer to monitor their steps activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Step goal
Description: Participants are given a daily step goal to aim for

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Step goal
Description: Participants are given a daily step goal to aim for

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Step goal
Description: Participants are given a daily step goal to aim for

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Consistent contexts
Description: Participants plan to take steps in contexts that are similar from day to day

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Inconsistent contexts
Description: Participants plan to take steps in contexts that vary from day to day
Study: NCT01817205

Intervention type: PROCEDURE
Group type: OTHER
Intervention: TACE with Hyperthermia Treatment
Description: Transcatheter arterial chemoembolization (TACE) is performed under local anesthesia with right femoral puncture. The feeding lobar hepatic artery is selectively catheterized for drug delivery.~Systemic hyperthermia is induced with an external energy source using microwave electromagnetic energy, with the patient lying supine on the treatment bed of the hyperthermia equipment, exposing the abdomen to the microwave transmitter.
Study: NCT03647514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: Tailored neoadjuvant chemotherapy with 4 cycles of PX(weekly Abraxane 125mg/m2, Q3week Xeloda 1250mg/m2, 21day/cycle) is planned for early breast cancer patients(stage of T2-4N0-3M0) who are eligible for primary systemic therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xeloda
Description: Tailored neoadjuvant chemotherapy with 4 cycles of PX(weekly Abraxane 125mg/m2, Q3week Xeloda 1250mg/m2, 21day/cycle) is planned for early breast cancer patients(stage of T2-4N0-3M0) who are eligible for primary systemic therapy.
Study: NCT04000165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-348
Description: This is a nonrandomized, intra-patient dose escalating clinical study. AG-348 will be administered starting at 5 mg twice a day, increasing to 20 mg twice a day, to maximum 50 mg or 100 mg twice a day. Dosing period is every 2 weeks at each dose level. Dose taper will start on Day 42 (50 mg) or Day 56 (100 mg) with dose reduced over 12 to 15 days.
Study: NCT03926182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AST2818 Tablets
Description: AST2818 Tablets: Period 1 Fasted from 10 hours prior to dosing with 80 mg AST2818 tablet (p o, once) and 4 hours after dosing on day 1. Period 2 Allocated high-fat meal prior to dosing with 80 mg AST2818 tablet (p o, once) and fasted 4 hours after dosing on day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AST2818 Tablets
Description: AST2818 Tablets: Period 1 allocated high-fat meal prior to dosing with 80 mg AST2818 tablet (p o, once) and fasted 4 hours after dosing on day 1. Period 2 fasted from 10 hours prior to dosing with 80 mg AST2818 tablet (p o, once)and 4 hours after dosing on day 1.
Study: NCT01201525

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulsed dye laser treatment
Description: Part 1 of the surgical scar will be treated with 4 595nm Pulsed dye laser treatments.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Part 2 of the surgical scar will serve as a within patient control.
Study: NCT03976349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB094
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB094
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB094
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB094
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB094
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as specified in the treatment arm.
Study: NCT04345887

Intervention type: DRUG
Intervention: Spironolactone 100mg
Description: 2x100 mg spironolactone for 5 consecutive days

Intervention type: DRUG
Intervention: Placebo oral tablet
Description: 2 x1 placebo tablet
Study: NCT01408303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omega-3-carboxylic acids, 4g
Description: Epanova: 4 x 1 g capsule daily for 6 weeks + prescription statin
Study: NCT02162134

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sugar free chewing gum
Description: Sugar free chewing gum (orbit) was given to patients. They were asked to chew it 4 hours after surgery and continue to chew it 8 hourly for 20 to 25 min each time until oral feeding was started.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sugared chewing gum
Description: Sugared chewing gum (singsong bubble gum) was given to patients. They were asked to chew it 4 hours after surgery and continue to chew it 8 hourly for 20 to 25 min each time until oral feeding was started.

Intervention type: DRUG
Group type: OTHER
Intervention: Tab. Midazolam 7.5 mg
Description: Tab. Midazolam 7.5 mg will be given to all patients at night before surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tab. Midazolam 7.5 mg
Description: Tab. Midazolam 7.5 mg will be given to all patients at night before surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tab. Midazolam 7.5 mg
Description: Tab. Midazolam 7.5 mg will be given to all patients at night before surgery.
Study: NCT01610323

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Description: Exercise group: 12 weeks of moderate intensity physical training under individual supervision in a specialised conditioning center, with a goal of 3 1h-sessions/week (from 16 wks to 28 wks of gestation). Including aerobic and muscular training.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Care
Study: NCT02172183

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Psychopharmacological treatment
Description: methylphenidate or atomoxetine

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT group
Study: NCT04150588

Intervention type: DRUG
Intervention: Efrin drops
Description: The amount that the eyelid rise after Erin drops before surgery

Intervention type: DRUG
Intervention: Efrin drops
Description: The amount that the eyelid rise after Erin drops before surgery
Study: NCT04030884

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Honey and water mixture
Description: 60 gr of organic Turkish BlackSea Region Chestnut Honey and 100 ml Spring water mixture both mixed in room temperature and ingested up to two hours before the surgery by participants who were nill by mouth from midnight prior to the operation day.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Honey and water mixture
Description: 60 gr of organic Turkish BlackSea Region Chestnut Honey and 100 ml Spring water mixture both mixed in room temperature and ingested up to two hours before the surgery by participants who were nill by mouth from midnight prior to the operation day.
Study: NCT02270840

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CRT-D
Description: Biventricular upgrade. Subjects meeting the inclusion criteria (and if exclusion criteria are not present) patients will be randomized to CRT-D upgrade or ICD only (either continued ICD therapy in patients currently implanted with a defibrillator or implantation of a defibrillator in eligible patients who are currently implanted with pacemaker-only).
Study: NCT02748616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodiol
Description: Subjects will begin to take 300 mg Ursodiol 2 (two) weeks after Visit #1 for a total of 8 (eight) weeks.